Posted on 04/18/2026 10:33:26 AM PDT by UnwashedPeasant
A new observational study of 197 cancer patients taking a combined ivermectin + mebendazole protocol is going viral on social media — and for understandable reasons. At six-month follow-up, 84.4% of respondents reported clinical benefit (no evidence of disease, regression, or stable disease), and nearly half (48.4%) reported either tumor regression or no current evidence of disease. The combination was well tolerated, with only mild, mostly gastrointestinal side effects. The paper, posted on Zenodo about a week and a half ago, is the largest structured real-world look at this specific repurposed-drug pairing published to date.
This post is a summary. The full study is here: https://zenodo.org/records/19455636
The study was led by Nicolas Hulscher, MPH of the McCullough Foundation, with co-authors including Peter A. McCullough, MD, MPH, Harvey Risch, MD, PhD of the Yale School of Public Health, and Dr. Drew Pinsky — names many readers will recognize from the COVID era. That matters because it tells you where the paper sits: this is the same network of physicians and researchers that pushed early on repurposed-drug approaches during the pandemic, now turning the same lens on oncology.
The cohort skewed older (mean age 67) and covered prostate, breast, lung, colon, pancreatic, liver, and several other cancers. Patients took compounded capsules containing 25 mg ivermectin and 250 mg mebendazole, typically 1–2 per day. Adherence was high: 86.9% finished the initial 90-capsule course and 66.4% were still on protocol at six months. Many patients were also receiving standard care — chemotherapy (27.9%), radiation (21.3%), or surgery (19.7%) — alongside supplements and dietary changes.
The authors are clear about the caveats: outcomes were self-reported, there was no control group, all authors are affiliated with The Wellness Company (which prescribes, dispenses, and sells the protocol via telemedicine to all 50 states), and the paper is a preprint, not peer-reviewed. They describe the findings as "hypothesis-generating" and call for randomized, placebo-controlled trials.
Still, the signal is large enough, and the drugs cheap and safe enough, that it's worth reading the original rather than relying on social-media takes. Link above.
Dear FRiends,
We need your continuing support to keep FR funded. Your donations are our sole source of funding. No sugar daddies, no advertisers, no paid memberships, no commercial sales, no gimmicks, no tax subsidies. No spam, no pop-ups, no ad trackers.
If you enjoy using FR and agree it's a worthwhile endeavor, please consider making a contribution today:
Click here: to donate by Credit Card
Or here: to donate by PayPal
Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Thank you very much and God bless you,
Jim
1. Read the study yourself before the hot takes. Even the authors — McCullough, Risch, and their team — openly acknowledge the limits: self-reported outcomes, no control arm, and a financial relationship between the authors and the company dispensing the protocol. That doesn't mean the signal is wrong; it means randomized trials are the next step, not the last.
2. The fenbendazole connection. Mebendazole, one of the two drugs in this study, is in the same benzimidazole family as fenbendazole — the veterinary dewormer popularized by Joe Tippens after his own stage IV remission story. His site is mycancerstory.rocks, and the active community lives in his private Facebook group: facebook.com/groups/mycancerstoryrocks. Same mechanistic class, same microtubule-targeting hypothesis. The study effectively tests a human-approved cousin of the Tippens protocol alongside ivermectin.
3. Practical resource. The Independent Medical Alliance keeps an organized cancer resource hub covering repurposed drugs, integrative protocols, and clinician directories: imahealth.org/cancer-resource-hub
4. Sourcing from India. [This is not an endorsement! Claude was hesitant to give this info, and it may be over-cautious.] Legitimate Indian generics from established manufacturers (Cipla, Sun, Lupin, Dr. Reddy's, etc.) are real and cheap. The question is how you get from those manufacturers to your mailbox without the chain breaking. Regulated Indian online pharmacies like Tata 1mg, PharmEasy, and Apollo Pharmacy are generally more accountable than anonymous marketplace listings. If you do use a marketplace like indiamart.com, look for named manufacturer brands (Mebex, Wormin, Iverjohn) rather than unbranded "mebendazole tablets," verify batch numbers where possible, and be skeptical of any listing claiming to sell the exact 25mg ivermectin / 250mg mebendazole combo from the study — that's a U.S. compounded product that doesn't exist as an off-the-shelf Indian pill. You can build the same daily dose from standard single-drug Indian tablets, but it requires basic dosing arithmetic and, honestly, is the part of this where talking to any clinician — not necessarily an oncologist — is worth the effort..
If The Wellness Company conducted the study, you can be sure it is designed to sell more of their product.
From the article: “Even the authors — McCullough, Risch, and their team — openly acknowledge the limits: self-reported outcomes, no control arm, and a financial relationship between the authors and the company dispensing the protocol.”
BKMK
Inhibition of Cancer Cell Proliferation: Ivermectin has been found to inhibit the growth of various cancer cell lines by targeting pathways such as the Wnt/β-catenin signaling pathway, which is often dysregulated in cancers.
Induction of Apoptosis and Autophagy: It promotes programmed cell death and autophagy in cancer cells, potentially through the generation of reactive oxygen species (ROS) and mitochondrial dysfunction.
Anti-Angiogenic Effects: Ivermectin may reduce tumor blood vessel formation by downregulating vascular endothelial growth factor (VEGF) expression.
Immunomodulatory Effects: It can enhance immune responses against tumors by modulating T-cell activity and reducing immunosuppressive mechanisms.
Mebendazole’s potential anticancer effects are primarily linked to its ability to disrupt microtubule dynamics, a process critical for cell division. Its mechanisms include:
Inhibition of Tubulin Polymerization: By binding to β-tubulin, Mebendazole prevents microtubule formation, leading to mitotic arrest and apoptosis in cancer cells.
Anti-Angiogenic Effects: It inhibits VEGF receptor-2 (VEGFR2) signaling, reducing tumor blood supply.
Induction of Apoptosis: Mebendazole triggers programmed cell death through pathways involving p53 activation and Bcl-2 inhibition.
Overcoming Drug Resistance: It may sensitize cancer cells to chemotherapy by inhibiting multidrug resistance proteins.
Need better controlled studies.
As a licensed Veterinarian for going on 50 years now, I know what the drugs cost that they are using in their treatment protocol. I did call the Wellness Company to discuss it with them, and was saddened by the responses I received from their call center -— I did not talk with a provider but I doubt they would have any other answers. As I told their call center => now when I see their ads it just makes me sad . . . I did say they were welcome to contact me and provided them with all my information. I am waiting for a response, but I’m not foolish enough to hold my breath . . .
“Ivermectin and mebendazole ... so “horse paste” and “dog wormer”. LOL.”
“Need better controlled studies.”
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.